BUSINESS WIRE: Olivier Danos Joins Biogen Idec as Senior Vice President, Gene Therapy

MITTEILUNG UEBERMITTELT VON BUSINESS WIRE. FUER DEN INHALT IST ALLEIN DAS BERICHTENDE UNTERNEHMEN VERANTWORTLICH.

Distinguished Scientist To Lead Companys Gene Therapy Research Efforts

CAMBRIDGE, Mass. --(BUSINESS WIRE)-- 23.09.2014 --

Biogen Idec (NASDAQ:BIIB) today announced that Olivier Danos, Ph.D., has joined the company as senior vice president, Gene Therapy. Dr. Danos reports directly to Douglas Williams, Ph.D., executive vice president, Research and Development, and is a member of Biogen Idecs Senior Research and Development Leadership Team.

Dr. Danos will lead the companys gene therapy research group, a team dedicated to identifying and developing new technologies for gene transfer and genome engineering. As part of his role, Dr. Danos will also identify potential collaborations that complement the companys internal capabilities and support the development of treatments across Biogen Idecs therapeutic focus areas.

Olivier is a true pioneer in the field. We believe that his expertise will help accelerate our development of a world-class gene therapy platform that combines our growing internal capabilities with collaborations with leading research organizations across the globe, said Dr. Williams. Our commitment to this important area will complement our existing capabilities in antisense, small molecule and biologics research, and enhance our ability to effectively and efficiently develop new treatments for people with serious diseases.

I have dedicated my career to advancing the use of gene therapy as a technology to develop life-saving therapies for patients, said Dr. Danos. The team at Biogen Idec shares this passion. It is their commitment to innovative science and willingness to tackle difficult medical challenges that attracted me to the company. I am excited about the opportunities before us.

Dr. Danos joins Biogen Idec from Kadmon Pharmaceuticals, where he served as senior vice president, Molecular Medicine, Synthetic Biology and Gene Regulation since 2011. In this role, he was instrumental in assembling a gene therapy program and a technology platform for the development ofcontrollablegene expression systems. Prior to Kadmon, Dr. Danos acted as the director of the Gene Therapy Consortium of the University College of London and led a gene therapy research team at the Necker Hospital Enfants Malades in Paris.

Dr. Danos also served as chief scientific officer at Genethon and senior director of research at Somatix Therapy Corporation. He has held several senior roles at the French National Centre for Scientific Research (CNRS) and at the Institut Pasteur in Paris. Dr. Danos is the former president and a founding member of the European Society of Gene and Cell Therapy.

Dr. Danos received a Masters in Genetics and Molecular Biology at University of ParisOrsay, and his Ph.D. in Biology at the Pasteur Institute and University of Paris Diderot.

The rest is here:
BUSINESS WIRE: Olivier Danos Joins Biogen Idec as Senior Vice President, Gene Therapy